TY - JOUR
T1 - Diastolic dysfunction and diastolic heart failure
T2 - Mechanisms and epidemiology
AU - Deswal, Anita
N1 - Funding Information:
Dr. Deswal is supported by a VA Cooperative Studies Program Advanced Clinical Research Career Development Award (# 712 A). This work is supported in part by grants from the Health Services Research & Development Service (# IIR 02-082-1) and the Clinical Science Research and Development Service of the Department of Veterans Affairs.
PY - 2005/5
Y1 - 2005/5
N2 - Studies have demonstrated that diastolic dysfunction is frequently present in asymptomatic community-based individuals, especially in the elderly with hypertension, coronary artery disease, and diabetes. The presence of diastolic dysfunction is a predictor for the development of heart failure (HF) and confers a higher risk of mortality. These findings have raised the question of whether treating preclinical diastolic dysfunction will be helpful in preventing or delaying the onset of clinical HF and mortality, as has been proven with treatment of asymptomatic left ventricular systolic dysfunction. In addition, in some individuals, diastolic dysfunction in the presence of a normal ejection fraction is associated with exercise intolerance as well as symptomatic clinical HF, referred to as diastolic HF. Patients with diastolic HF, who are more often elderly women, have a significant mortality and morbidity burden compared with age-matched controls. Studies that further our understanding of mechanisms underlying diastolic dysfunction and diastolic HF will provide potential new targets for development of effective therapies for these conditions.
AB - Studies have demonstrated that diastolic dysfunction is frequently present in asymptomatic community-based individuals, especially in the elderly with hypertension, coronary artery disease, and diabetes. The presence of diastolic dysfunction is a predictor for the development of heart failure (HF) and confers a higher risk of mortality. These findings have raised the question of whether treating preclinical diastolic dysfunction will be helpful in preventing or delaying the onset of clinical HF and mortality, as has been proven with treatment of asymptomatic left ventricular systolic dysfunction. In addition, in some individuals, diastolic dysfunction in the presence of a normal ejection fraction is associated with exercise intolerance as well as symptomatic clinical HF, referred to as diastolic HF. Patients with diastolic HF, who are more often elderly women, have a significant mortality and morbidity burden compared with age-matched controls. Studies that further our understanding of mechanisms underlying diastolic dysfunction and diastolic HF will provide potential new targets for development of effective therapies for these conditions.
UR - http://www.scopus.com/inward/record.url?scp=23844549581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23844549581&partnerID=8YFLogxK
U2 - 10.1007/s11886-005-0074-7
DO - 10.1007/s11886-005-0074-7
M3 - Review article
C2 - 15865857
AN - SCOPUS:23844549581
SN - 1523-3782
VL - 7
SP - 178
EP - 183
JO - Current Cardiology Reports
JF - Current Cardiology Reports
IS - 3
ER -